100 related articles for article (PubMed ID: 2735769)
1. [Combination chemotherapy of multiple myeloma--BCNU.cyclophosphamide.procarbazine.prednisolone and MCNU.cyclophosphamide.procarbazine.prednisolone therapy].
Uzuka Y; Saito Y; Takahashi H; Komatsu M; Ito T
Gan To Kagaku Ryoho; 1989 Jun; 16(6):2269-73. PubMed ID: 2735769
[TBL] [Abstract][Full Text] [Related]
2. [Combination chemotherapy of multiple myeloma].
Uzuka Y; Saito Y; Ito T
Gan To Kagaku Ryoho; 1990 Aug; 17(8 Pt 1):1481-7. PubMed ID: 2389944
[TBL] [Abstract][Full Text] [Related]
3. [Combination chemotherapy of MCNU, melphalan, procarbazine, and prednisolone (MMPP) in multiple myeloma; disappearance of M-peak on serum electrophoretic pattern].
Kamiya O; Hoshino A; Ohara K; Nagata K; Ono Y; Saito M; Itou T; Yamamoto K
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 1):863-5. PubMed ID: 2469398
[No Abstract] [Full Text] [Related]
4. Combination chemotherapy with MCNU, vindesine, melphalan, and prednisolone (MCNU-VMP therapy) in induction therapy for multiple myeloma. Japan Myeloma Study Group.
Imamura Y; Takagi T; Yawata Y; Nishinarita S; Kosaka M; Mikuni C; Takatsuki K; Sezaki T; Mori M; Tsuchiya J
Int J Hematol; 1994 Feb; 59(2):113-23. PubMed ID: 8018904
[TBL] [Abstract][Full Text] [Related]
5. Combination chemotherapy for multiple myeloma with melphalan, prednisone, cyclophosphamide, vincristine, and carmustine (BCNU) (M-2 protocol).
Tirelli U; Crivellari D; Carbone A; Veronesi A; Galligioni E; Trovò MG; Tumolo S; Grigoletto E
Cancer Treat Rep; 1982 Nov; 66(11):1971-3. PubMed ID: 6897205
[TBL] [Abstract][Full Text] [Related]
6. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479.
Oken MM; Harrington DP; Abramson N; Kyle RA; Knospe W; Glick JH
Cancer; 1997 Apr; 79(8):1561-7. PubMed ID: 9118039
[TBL] [Abstract][Full Text] [Related]
7. [Trial of combination chemotherapy for multiple myeloma and macroglobulinemia--VENAP therapy (author's transl)].
Furukawa K; Fujiwara Y; Nakaide Y; Tanaka M; Tanaka M; Hirota Y
Rinsho Ketsueki; 1980 Nov; 21(11):1683-91. PubMed ID: 6782278
[No Abstract] [Full Text] [Related]
8. The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486.
Oken MM; Leong T; Lenhard RE; Greipp PR; Kay NE; Van Ness B; Keimowitz RM; Kyle RA
Cancer; 1999 Sep; 86(6):957-68. PubMed ID: 10491521
[TBL] [Abstract][Full Text] [Related]
9. [Recent therapy for refractory myeloma].
Togawa A
Rinsho Ketsueki; 1993 Apr; 34(4):450-4. PubMed ID: 8510332
[TBL] [Abstract][Full Text] [Related]
10. [Study on the therapy of multiple myelomas--initial induction therapy (MP, IFN alpha, steroid pulse) and maintenance therapy (VMP, MP continuous, VEP, MCNU)].
Tanaka H; Kawano M; Iwato K; Asaoku H; Tanabe O; Ishikawa H; Nobuyoshi M; Sakai A; Kuramoto A
Rinsho Ketsueki; 1992 May; 33(5):655-61. PubMed ID: 1630017
[TBL] [Abstract][Full Text] [Related]
11. Satisfactory remission in a case of IgD myeloma: effectiveness of glucocorticoid treatment.
Takemori N; Kondo K; Kawamura T; Imai K; Sakurai H; Sato T
Am J Hematol; 2001 Jan; 66(1):62-3. PubMed ID: 11426497
[TBL] [Abstract][Full Text] [Related]
12. A randomized study comparing VMCP and MMPP in the treatment of multiple myeloma.
Nagura E; Ichikawa A; Kamiya O; Kato R; Utsumi M; Tanaka M; Takeyama H; Shimizu K; Kobayashi M; Naito K; Nishiwaki H; Mizuno H; Hirabayashi N; Nitta M; Kato Y; Shibata T; Hotta T; Kawashima K; Saito H
Cancer Chemother Pharmacol; 1997; 39(4):279-85. PubMed ID: 9025767
[TBL] [Abstract][Full Text] [Related]
13. [Four cases of therapy-related leukemia in multiple myeloma].
Natori K; Izumi H; Kaneko K; Ishihara S; Nagase D; Fujimoto Y; Kato M; Umeda M; Kuraishi Y
Gan To Kagaku Ryoho; 2007 Jan; 34(1):121-4. PubMed ID: 17220686
[TBL] [Abstract][Full Text] [Related]
14. [Combination chemotherapy of Hodgkin's disease with vincristine, cyclophosphamide, procarbazine, and prednisolone].
Aiba K; Ogawa M; Inagaki J; Horikoshi N; Ezaki K; Inoue K; Dohmyo M; Nagata T; Miyamoto H; Kobayashi T; Kuraishi Y
Gan To Kagaku Ryoho; 1982 Nov; 9(11):1928-32. PubMed ID: 6897857
[TBL] [Abstract][Full Text] [Related]
15. [New protocols for myeloma chemotherapy plus IFN alpha].
Kitani T
Rinsho Ketsueki; 1993 Apr; 34(4):455-9. PubMed ID: 8510333
[TBL] [Abstract][Full Text] [Related]
16. The association of cyclophosphamide and dexamethasone in advanced refractory multiple myeloma patients.
Celesti L; Clavio M; Poggi A; Casciaro S; Vallebella E; Gobbi M
Haematologica; 1997; 82(3):351-3. PubMed ID: 9234590
[TBL] [Abstract][Full Text] [Related]
17. The therapeutic efficacy of VBCMP-M2 protocol in multiple myeloma.
Colović MD; Janković GM; Nikolov VS; Suvajdzić ND; Miletić VD
Haematologia (Budap); 1994; 26(2):91-6. PubMed ID: 7890267
[TBL] [Abstract][Full Text] [Related]
18. [Treatment of multiple myeloma. High-dose intermittent administration of cyclophosphamide and prednisolone--follow up study of 10 years period].
Mizuno H; Ninomiya N; Ohta H; Tokoro K; Yasuma A; Ohnishi K; Ikeda Y
Gan To Kagaku Ryoho; 1983 Nov; 10(11):2286-91. PubMed ID: 6639091
[TBL] [Abstract][Full Text] [Related]
19. Phase III study of intermittent carmustine (BCNU), cyclophosphamide, and prednisone versus intermittent melphalan and prednisone in myeloma.
Abramson N; Lurie P; Mietlowski WL; Schilling A; Bennett JM; Horton J
Cancer Treat Rep; 1982 Jun; 66(6):1273-7. PubMed ID: 7044535
[TBL] [Abstract][Full Text] [Related]
20. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
Montoto S; Camós M; López-Guillermo A; Bosch F; Cervantes F; Blandé J; Esteve J; Cobo F; Nomdedeu B; Campo E; Montserrat E
Cancer; 2000 May; 88(9):2142-8. PubMed ID: 10813727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
